4-tert-butyl-N-(6-chloro-5-(2-methoxyphenyl)thio-4-pyrimidinyl)benzenesulfonamide | 167403-91-0

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 4-tert-butyl-N-(6-chloro-5-(2-methoxyphenyl)thio-4-pyrimidinyl)benzenesulfonamide
• 英文别名: 4-tert-butyl-N-[6-chloro-5-(2-methoxy-phenylsulfanyl)-pyrimidin-4-yl]-benzenesulfonamide；4-tert-butyl-N-[6-chloro-5-(2-methoxyphenyl)sulfanylpyrimidin-4-yl]benzenesulfonamide
• CAS: 167403-91-0
• 化学式: C₂₁H₂₂ClN₃O₃S₂
• 分子量: 464.009
• InChiKey: SMBCYCPELLLENU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  115
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-tert-butyl-N-(6-chloro-5-(2-methoxyphenyl)thio-4-pyrimidinyl)benzenesulfonamide 在 sodium hydride 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 5.58h， 生成 4-tert-butyl-N-{6-[2-(5-bromopyrimidin-2-yloxy)ethoxy]-5-(2-methoxyphenylthio)pyrimidin-4-yl}benzenesulfonamide
  参考文献：
  名称：

  Potent and Selective ET-A Antagonists. 1. Syntheses and Structure−Activity Relationships of N-(6-(2-(Aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide Derivatives

  摘要：

  Modifications to the ETA/B mixed type compounds 1 (Ro. 46-2005) and 2 (bosentan) were performed. Introduction of a pyrimidine group into 1 resulted in a dramatic increase in affinity for the ETA receptor, and the subsequent optimization of substituents on the pyrimidine ring led us to the discovery of N-(6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-5-(4-methylphenyl)-4pyrimidinyl)-4-tert-butylbenzenesulfonamide (7k), which showed an extremely high affinity for the human cloned ETA receptor (K-i = 0.0042 +/-0.0038 nM) and an ETA/B receptor selectivity up to 29 000 (K-i = 130 +/- 50 nM for the human cloned ETB receptor). The compound was designed on the hypothesis that the hydrogen atom of the hydroxyl group in 1 and 2 played a role not as a proton donor but as an acceptor in the possible hydrogen bonding with Tyr129. Since the incorporation of a pyrimidinyl group into the hydroxyethoxy side chain of the nonselective antagonist (1) dramatically enhanced both the ETA receptor affinity and selectivity, and since similar results were obtained from the benzene analogues, we put forward the hypothesis that a "pyrimidine binding pocket" might exist in the ETA receptor.

  DOI：

  10.1021/jm0102304
• 作为产物：
  描述：

  对叔丁基苯磺酰氯 在 ammonium hydroxide 、 potassium carbonate 作用下， 以 二甲基亚砜 、 乙酸乙酯 为溶剂， 反应 2.0h， 生成 4-tert-butyl-N-(6-chloro-5-(2-methoxyphenyl)thio-4-pyrimidinyl)benzenesulfonamide
  参考文献：
  名称：

  Potent and Selective ET-A Antagonists. 1. Syntheses and Structure−Activity Relationships of N-(6-(2-(Aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide Derivatives

  摘要：

  Modifications to the ETA/B mixed type compounds 1 (Ro. 46-2005) and 2 (bosentan) were performed. Introduction of a pyrimidine group into 1 resulted in a dramatic increase in affinity for the ETA receptor, and the subsequent optimization of substituents on the pyrimidine ring led us to the discovery of N-(6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-5-(4-methylphenyl)-4pyrimidinyl)-4-tert-butylbenzenesulfonamide (7k), which showed an extremely high affinity for the human cloned ETA receptor (K-i = 0.0042 +/-0.0038 nM) and an ETA/B receptor selectivity up to 29 000 (K-i = 130 +/- 50 nM for the human cloned ETB receptor). The compound was designed on the hypothesis that the hydrogen atom of the hydroxyl group in 1 and 2 played a role not as a proton donor but as an acceptor in the possible hydrogen bonding with Tyr129. Since the incorporation of a pyrimidinyl group into the hydroxyethoxy side chain of the nonselective antagonist (1) dramatically enhanced both the ETA receptor affinity and selectivity, and since similar results were obtained from the benzene analogues, we put forward the hypothesis that a "pyrimidine binding pocket" might exist in the ETA receptor.

  DOI：

  10.1021/jm0102304

文献信息

• Sulfonylaminopyrimidines
  申请人：Hoffmann-La Roche Inc.

  公开号：US05541186A1

  公开（公告）日：1996-07-30

  A compound of the formula ##STR1## wherein R.sup.1 to R, R.sup.a, R.sup.b X, Y, Z, m and n have the significance given in the description, can be used as medicaments, especially for the treatment and prophylaxix of conditions which are associated with endothelin activities.

  其中R.sup.1至R，R.sup.a，R.sup.b，X，Y，Z，m和n具有描述中给定的含义的式##STR1##的化合物，可用作药物，特别用于与内皮素活性相关的疾病的治疗和预防。
• Neue Sulfonylaminopyrimidine, ihre Herstellung und Verwendung als Heilmittel
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0633259A1

  公开（公告）日：1995-01-11

  Verbindungen der Formel worin R¹ bis R⁹, Ra, Rb, X, Y, Z, m und n die in der Beschreibung angegebene Bedeutung haben, können als Heilmittel, insbesondere zur Behandlung und Prophylaxe von mit Endothelinaktivitäten assoziierten Zuständen Verwendung finden.

  式中的化合物 其中 R¹ 至 R⁹、Ra、Rb、X、Y、Z、m 和 n 具有说明中给出的含义，可用作治疗剂，特别是用于治疗和预防与内皮素活性相关的疾病。
• Sulfonylaminopyrimidine, ihre Herstellung und Verwendung als Heilmittel
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0633259B1

  公开（公告）日：1999-01-13
• US5541186A
  申请人：——

  公开号：US5541186A

  公开（公告）日：1996-07-30
• Potent and Selective ET-A Antagonists. 1. Syntheses and Structure−Activity Relationships of <i>N</i>-(6-(2-(Aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide Derivatives
  作者：Hiroshi Morimoto、Hideshi Shimadzu、Emi Kushiyama、Hiroyuki Kawanishi、Toshihiro Hosaka、Yasushi Kawase、Kosuke Yasuda、Kohei Kikkawa、Rikako Yamauchi-Kohno、Koichiro Yamada

  DOI：10.1021/jm0102304

  日期：2001.10.1

  Modifications to the ETA/B mixed type compounds 1 (Ro. 46-2005) and 2 (bosentan) were performed. Introduction of a pyrimidine group into 1 resulted in a dramatic increase in affinity for the ETA receptor, and the subsequent optimization of substituents on the pyrimidine ring led us to the discovery of N-(6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-5-(4-methylphenyl)-4pyrimidinyl)-4-tert-butylbenzenesulfonamide (7k), which showed an extremely high affinity for the human cloned ETA receptor (K-i = 0.0042 +/-0.0038 nM) and an ETA/B receptor selectivity up to 29 000 (K-i = 130 +/- 50 nM for the human cloned ETB receptor). The compound was designed on the hypothesis that the hydrogen atom of the hydroxyl group in 1 and 2 played a role not as a proton donor but as an acceptor in the possible hydrogen bonding with Tyr129. Since the incorporation of a pyrimidinyl group into the hydroxyethoxy side chain of the nonselective antagonist (1) dramatically enhanced both the ETA receptor affinity and selectivity, and since similar results were obtained from the benzene analogues, we put forward the hypothesis that a "pyrimidine binding pocket" might exist in the ETA receptor.